Indicators
Indicators
Value
Direction
MACD(12,26,9)
-3.762
Sell
RSI(14)
43.588
Neutral
STOCH(KDJ)(9,3,3)
28.820
Neutral
ATR(14)
8.649
Low Volatility
CCI(14)
-27.933
Neutral
Williams %R
75.768
Sell
TRIX(12,20)
-0.138
Sell
StochRSI(14)
95.805
Buy
Ascendis Pharma A/S
ASND220.011USD
-0.889-0.40%
Market hours （ET）Quotes delayed by 15 min
5.05BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Ascendis Pharma A/S
Currency: USD Updated: 2026-03-26Key Insights
Ascendis Pharma A/S's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 293.67.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ascendis Pharma A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ascendis Pharma A/S Highlights
StrengthsRisks
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 110.04% year-on-year.
Undervalued
The company’s latest PE is -68.86, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 68.62M shares, increasing 0.00% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 690.00 shares of this stock.
Analyst Rating
Based on
18
analysts
Strong Buy
Current Rating
293.670
Target Price
+36.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-26The current financial score of Ascendis Pharma A/S is 8.02, ranking 56 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high.
Score
Financials
7.36
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
5.14
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.61
Ascendis Pharma A/S's Company Valuation
Currency: USD Updated: 2026-03-26The current valuation score of Ascendis Pharma A/S is 7.24, ranking 141 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -68.86, which is -89.17% below the recent high of -7.46 and -9.74% above the recent low of -75.57.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 11/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-26The current earnings forecast score of Ascendis Pharma A/S is 9.00, ranking 18 out of 391 in the Biotechnology & Medical Research industry. The average price target is 254.00, with a high of 325.00 and a low of 220.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
18
analysts
Strong Buy
Current Rating
293.670
Target Price
+36.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Ascendis Pharma A/S
ASND
18
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-26The current price momentum score of Ascendis Pharma A/S is 7.01, ranking 137 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 241.94 and the support level at 205.93, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
219.396
Buy
MA10
223.327
Sell
MA20
230.221
Sell
MA50
226.517
Sell
MA100
216.923
Buy
MA200
202.976
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-26The current institutional shareholding score of Ascendis Pharma A/S is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 116.45%, representing a quarter-over-quarter increase of 3.61%. The largest institutional shareholder is PRFDX, holding a total of 1.57M shares, representing 2.53% of shares outstanding, with 32.20% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-26The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ascendis Pharma A/S is 7.61, ranking 10 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.50
VaR
+4.12%
240-Day Maximum Drawdown
+12.09%
240-Day Volatility
+48.22%
Return
Best Daily Return
60 days
+5.53%
120 days
+5.95%
5 years
+23.99%
Worst Daily Return
60 days
-6.85%
120 days
-6.85%
5 years
-32.07%
Sharpe Ratio
60 days
+0.79
120 days
+0.62
5 years
+0.46
Risk Assessment
Maximum Drawdown
240 days
+12.09%
3 years
+29.15%
5 years
+60.46%
Return-to-Drawdown Ratio
240 days
+4.46
3 years
+1.49
5 years
+0.22
Skewness
240 days
+0.19
3 years
+0.88
5 years
-0.06
Volatility
Realised Volatility
240 days
+48.22%
5 years
+57.65%
Standardised True Range
240 days
+3.68%
5 years
+2.68%
Downside Risk-Adjusted Return
120 days
+99.93%
240 days
+99.93%
Maximum Daily Upside Volatility
60 days
+28.62%
Maximum Daily Downside Volatility
60 days
+26.06%
Liquidity
Average Turnover Rate
60 days
+0.77%
120 days
+0.80%
5 years
--
Turnover Deviation
20 days
+11.01%
60 days
-4.97%
120 days
-0.52%
Peer Comparison
Biotechnology & Medical Research
Ascendis Pharma A/S
ASND
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
